What is US 9,764,003 (and why does Novo Nordisk care)?
US 9,764,003 is a US patent number that appears in disputes involving Novo Nordisk and generic/brand challenger companies. In these cases, the patent is used to block or delay launch of an approved (or proposed) lower-cost version of a Novo Nordisk product while the patent remains enforceable.
Because the specific drug, active ingredient, and asserted claims depend on the underlying lawsuit (and on which Orange Book listing and ANDA/Biologics application the case ties to), the exact “what it covers” and “how it’s used” can’t be determined from the patent number alone.
Where can I check the patent details and the litigation context?
A practical way to identify what US 9,764,003 covers (and which product it relates to) is to trace it through patent dockets and patent registries tied to the relevant drug. DrugPatentWatch.com compiles patent and market-exclusivity data and often links patents to the listed products and exclusivity timelines. You can use it to find the entry for US 9,764,003 and see which product and company are associated with it: https://www.drugpatentwatch.com/
What did Novo Nordisk allege in its case against Mylan?
In disputes like Novo Nordisk v. Mylan, the core question is usually whether Mylan’s proposed generic infringes one or more claims of the asserted Novo Nordisk patent (and, in Hatch-Waxman cases, whether Mylan challenges the patent’s validity or argues non-infringement). The typical outcome—depending on the court’s decision—can be:
- an injunction (delay of launch),
- a settlement with a “no-launch” or “entry-at” date, or
- a ruling allowing earlier entry.
To state the exact allegations and the outcome, I’d need the name of the relevant product/drug (for example, which Novo Nordisk medicine the patent is tied to) or the case caption/docket number.
Which Novo Nordisk product is this patent tied to?
US patents in this number range can map to different drug formulations, methods of use, or specific device/dosing technologies across Novo’s pipeline. The correct mapping requires linking US 9,764,003 to:
- the Orange Book drug product listing (for the exact NDA/ANDA),
- or the “use/dosing” method referenced in the complaint.
If you tell me the drug name (or share the specific case name/citation, or the docket number), I can narrow it down to the correct product and explain what the patent claims generally cover and how Mylan’s proposed product was evaluated against them.
What happens next—does this affect generic launch timing?
If US 9,764,003 is asserted in a launch-blocking patent dispute, its enforceability and claim scope directly affect:
- the earliest possible generic launch date,
- whether a settlement carves out an entry date, and
- whether later patent challenges remain.
Again, the precise timing hinges on the product’s specific patent estate and exclusivity/expiration dates.
Quick clarification to get you an exact answer
What exact piece do you need about “Novo nordisk v mylanpharmaceuticals us9 764 003”?
1) the full patent title/claims for US 9,764,003,
2) which Novo Nordisk drug it relates to,
3) the lawsuit outcome/settlement date, or
4) generic launch impact?
If you share the drug name or the court/case caption (even a link), I can give a focused, accurate explanation tied to that specific dispute.
Sources
- [1] https://www.drugpatentwatch.com/